Loading clinical trials...
Loading clinical trials...
Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent
Conditions
Interventions
AZD9291 40 mg
AZD9291 80 mg
Locations
2
China
Research Site
Guangzhou, China
Research Site
Shanghai, China
Start Date
August 24, 2015
Primary Completion Date
January 28, 2016
Completion Date
September 27, 2019
Last Updated
February 11, 2020
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions